Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-Term Debt issuances (2017 - 2025)

Myriad Genetics (MYGN) has disclosed Short-Term Debt issuances for 5 consecutive years, with $40.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Short-Term Debt issuances fell 33.33% to $40.0 million in Q1 2025 year-over-year; TTM through Dec 2025 was $40.0 million, a 66.67% decrease, with the full-year FY2025 number at $40.0 million, down 66.67% from a year prior.
  • Short-Term Debt issuances was $40.0 million for Q1 2025 at Myriad Genetics, up from $20.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $60.0 million in Q1 2024 to a low of $20.0 million in Q2 2024.
  • A 3-year average of $34.3 million and a median of $40.0 million in 2023 define the central range for Short-Term Debt issuances.
  • Peak YoY movement for Short-Term Debt issuances: crashed 50.0% in 2024, then crashed 33.33% in 2025.
  • Myriad Genetics' Short-Term Debt issuances stood at $40.0 million in 2023, then plummeted by 50.0% to $20.0 million in 2024, then surged by 100.0% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Short-Term Debt issuances are $40.0 million (Q1 2025), $20.0 million (Q4 2024), and $20.0 million (Q3 2024).